Reach4Entertainment – 2019 results, “confidence in the group's ability to withstand the current situation”...BUY
As I explained in some detail in my first new video show three weeks ago, Novacyt (NCYT) senior managers, notably CEO Graham Mullis, are massively incentivised to ramp the shares as hard as they can up to October 17. If they achieve peak ramp they will clean out the company’s cash reserves, leaving the PLC gasping for breath as they shout “Ching! Ching! And buy top of the range Porsches.” The full scheme is explained HERE
In April and May we were at peak Covid hysteria. Across the world authorities like the disgraced Public Health England which had shamed themselves by having limited supplies of PPE and other items hastened to order as many Covid tests as they could. Now they are well stocked by testing at way under capacity. So what is going on and why should Novacyt (NCYT) care?
In yesterday's new video show I explained why Novacyt (NCYT) shares were 90% overvalued and presented damning new evidence of the management ramp. Yet immediately a raft of twitter fools - who clearly do not listen to what I have repeatedly said about this stock - accused me of a volte face? And one particularly deranged individual showed "evidence" of me ramping the stock on May 18. Hang on Henry! This is market abuse. It's personation. It's fraud.
I do not deny, nor have I ever denied, that Novacyt (NCYT) is a winner from Coronavirus but the data out today must make you reflect on the past, present and future and conclude that the valuation, £213 million at 372p, is just insane.
Hello, Share Mashers. Most of you will be hopeful about the current rise in share prices. But when the real recovery finally gets underway, a few companies will deliver to rally their share prices to outdo previous levels. Obviously, a few medical companies could shine here. I’ve looked at a few contenders over the last fortnight, but here’s another one you may wish to keep track of...
I wondered how long it would take before people started trying to cash in off of the back of coronavirus and pushing shares in small AIM listed companies that are supposedly going to make a fortune from this outbreak.
AIM-listed diagnostics play Novacyt (NCYT) announced a death spiral deal on 23 April 2019 and at 6.23pm on Friday evening it slipped out details of the first two rounds of conversions – at no-one-is-watching o’clock….except ShareProphets was watching. It is also listed on the Euronext Growth market (ALNOV), and joined AIM at the back end of 2017 – since when it has been heading heavily southwards, as you can see from the chart below.
Search ShareProphets |
Recent Comments |